CCL2 and early-onset autosomal dominant Alzheimer disease: Oral administration of a bioactive milk tripeptide inhibits the expression of inflammatory factors such as TNF-α, CCL2 or iNOS in the hippocampus of the Alzheimer’s disease mice model [39].